Beta-blocker therapy and physical activity after myocardial infarction: a preplanned sub-study of the BETAMI trial
Open Access
- 11 August 2026
- journal article
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Abstract
Aims: To investigate the effect of long-term beta-blocker therapy on physical activity (PA) level after myocardial infarction (MI) in patients without heart failure. Methods and results: The BETAMI trial randomized patients hospitalized with a MI without heart failure (LVEF ≥40%) to beta-blocker or no beta-blocker. In this preplanned sub-study, PA level was assessed by guideline-recommended PA level (≥30 min moderate activity ≥5 days/week) or not and self-reported hours/week with light to moderate and vigorous PA. Between-group differences in PA from baseline before randomization to 18-months were estimated by linear mixed models. Exploratory analysis assessed treatment effects on a composite of all-cause mortality and major adverse cardiovascular events using a Cox proportional hazards model. Of the 2867 randomized patients, 2185 (76%) responded to the PA questions and were included in this analysis. Mean age was 62.5 (SD 10.1) years, and 20.6% were women. No differences in guideline-recommended PA level or mean hours of light to moderate and vigorous PA were reported between the beta-blocker and non-beta-blocker group at baseline or during 18-month follow-up. At 12-month follow-up, 37.0% in the beta-blocker group and 36.7% in the no beta-blocker group reported guideline-recommended PA level (OR 0.97, 95% CI 0.69–1.37). Exploratory, hypothesis-generating analyses did not demonstrate a statistically significant interaction (P for interaction = 0.06) between treatment assignment and baseline PA level for recurrent clinical events. Conclusion: Beta-blocker therapy did not result in a change in PA level in post-MI patients without heart failure during the 18-month follow-up. Registration: ClinicalTrials.gov. URL: https://clinicaltrials.gov/search?term==NCT03646357. Unique identifier: NCT03646357, registered on 23 August 2018.Keywords
Funding Information
- Health South-East research program (2017205)
- Norges Forskningsråd (302454)
This publication has 27 references indexed in Scilit:
- Beta-blocker side-effects in clinical practice: A nationwide approachAmerican Heart Journal, 2025
- Cardiac rehabilitation and improvement of chronotropic incompetence: Is it the exercise or just the beta blockers?Revista Portuguesa de Cardiologia, 2021
- The Impact of beta blockade on the cardio-respiratory system and symptoms during exerciseCurrent Research in Physiology, 2021
- Bloqueadores beta: perspectiva histórica y mecanismos de acciónRevista Espanola de Cardiologia, 2019
- BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point studyAmerican Heart Journal, 2019
- Barriers to Beta-Blocker Use and Up-Titration Among Patients with Heart Failure with Reduced Ejection FractionCardiovascular Drugs and Therapy, 2017
- Lessons from contemporary trials of cardiovascular prevention and rehabilitation: A systematic review and meta-analysisInternational Journal of Cardiology, 2017
- Influence of β-blockers on heart rate recovery and rating of perceived exertion when determining training intensity for cardiac rehabilitationJournal of the Chinese Medical Association, 2015
- Reliability and validity of self-reported physical activity in the Nord-Trøndelag Health Study (HUNT 2)European Journal of Epidemiology, 2007
- A Randomized Trial of Propranolol in Patients With Acute Myocardial InfarctionJAMA, 1982